Yangxue Qingnao pill
PreclinicalSmall molecule
Yangxue Qingnao pill is one of 65 small molecule programs targeting Cognitive impairment. It is currently in Preclinical.
3
Indications
3
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
69 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Azilect
TevaApproved
Marinol
Jazz PharmaceuticalsApproved
Brintellix
TakedaApproved
Intropin
PfizerApproved
Avandia
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Nimotop
AAzurity Pharmaceuticals
Approved
Coumadin
AAbbott
Approved
Pradaxa
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cerebral Infarction1 trial
Cognitive impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Yangxue Qingnao pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University Third Hospital